Orchestra BioMed Holdings, Inc. (OBIO) Q2 2024 Earnings

OBIO·Reported August 12, 2024·Before market open

Orchestra BioMed Holdings, Inc. reported Q2 2024 revenue of $778.0K, missed analyst consensus of $850.0K by $72.0K. Diluted EPS came in at $-0.45, missed the $-0.41 consensus by $0.04.

Revenue

$778.0Kmissed by $72.0K

Consensus: $850.0K

Diluted EPS

$-0.45missed by $0.04

Consensus: $-0.41

SEC Filings

Earnings release8-K not filed yet

Quarterly report10-Q · 0001558370-24-011899

Financial Snapshot

Trailing eight quarters through Q2 2024

View all metrics

Revenue

Net Income

Operating Cash Flow

EPS (Diluted)

Q2 2024 Earnings FAQ

Common questions about Orchestra BioMed Holdings, Inc.'s Q2 2024 earnings report.

Orchestra BioMed Holdings, Inc. (OBIO) reported Q2 2024 earnings on August 12, 2024 before market open.

Orchestra BioMed Holdings, Inc. reported revenue of $778.0K and diluted EPS of $-0.45 for Q2 2024.

Revenue missed the consensus estimate of $850.0K by $72.0K. EPS missed the consensus estimate of $-0.41 by $0.04.

You can read the 10-Q periodic report (0001558370-24-011899) directly on SEC EDGAR. The filing index links above go to sec.gov.